Contribution: Innovation for Defence Excellence and Security Program
ONCOVIR CANADA INC
$2,099,792.00
Clinical Study of Safety and Immunogenicity of Nasal Poly-ICLC (Hiltonol®) for Prophylaxis of COVID-19 in Healthy Adults
FY 2020-21 · 2021-03-18
Summary
The overall goal of this project is to advance the clinical development of Poly-ICLC (Hiltonol®), a broad-spectrum antiviral drug candidate, as an innovative solution to strengthen medical preparedness against viral threats.
Department
Program
Innovation for Defence Excellence and Security ProgramInnovation for Defence Excellence and Security Program (linked with high confidence)
Recipient
Location
Vancouver, British Columbia, Canada
Recipient Type
For-profit organization
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
As published
Agreement End Date
2022-03-31
Agreement Start Date
2021-03-18
Agreement Title
Clinical Study of Safety and Immunogenicity of Nasal Poly-ICLC (Hiltonol®) for Prophylaxis of COVID-19 in Healthy Adults
Agreement Type
Contribution
Agreement Value
$2,099,792.00
Amendment Number
0
Description
The overall goal of this project is to advance the clinical development of Poly-ICLC (Hiltonol®), a broad-spectrum antiviral drug candidate, as an innovative solution to strengthen medical preparedness against viral threats.
Description (French)
L'objectif du projet est de faire progresser le développement clinique du Poly-ICLC (Hiltonol®), un candidat médicament antiviral à large spectre, comme solution innovante pour renforcer la préparation médicale contre les menaces virales.
Organization Code
dnd-mdn
Organization
National Defence | Défense nationale
Program Name
Innovation for Defence Excellence and Security Program
Program Name (French)
Programme d’innovation pour la défense, l’excellence et la sécurité
Recipient City
Vancouver
Recipient Country
CA
Recipient Legal Name
ONCOVIR CANADA INC
Recipient Operating Name
ONCOVIR CANADA INC
Recipient Province or Territory
BC
Recipient Type
F
Reference Number
032-2020-2021-Q4-00010
